Bruker Corporation (BRKR) is likely to grow in the coming quarters due to the solid prospects of the Bruker Scientific Instruments (“BSI”) Nano and BioSpin group. The addition of PhenomeX complements the Bruker cellular and sub-cellular analysis tools and brings opportunities for commercial synergies. However, BRKR’s operations are subject to intense competition from its peers in the industry. In the past year, this Zacks Rank #3 (Hold) stock has increased 5% against the 14.2% fall of the industry and a 22. ...